Raphi Levy Sells 17,500 Shares of Alpha Tau Medical (NASDAQ:DRTS) Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 17,500 shares of Alpha Tau Medical stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $9.55, for a total transaction of $167,125.00. Following the sale, the chief financial officer directly owned 130,180 shares of the company’s stock, valued at $1,243,219. This represents a 11.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total value of $220,000.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Trading Down 2.6%

Shares of NASDAQ DRTS opened at $10.88 on Friday. Alpha Tau Medical Ltd. has a twelve month low of $2.87 and a twelve month high of $11.62. The firm has a market cap of $982.79 million, a PE ratio of -16.24 and a beta of 1.19. The business has a fifty day simple moving average of $9.39 and a two-hundred day simple moving average of $7.61. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.09.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). Analysts expect that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alpha Tau Medical

Several hedge funds have recently made changes to their positions in the company. Apella Capital LLC purchased a new position in Alpha Tau Medical in the 4th quarter worth $1,892,000. Daytona Street Capital LLC acquired a new position in shares of Alpha Tau Medical in the fourth quarter valued at about $749,000. Mariner LLC increased its holdings in shares of Alpha Tau Medical by 185.8% in the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after purchasing an additional 80,129 shares during the period. Millennium Management LLC raised its stake in shares of Alpha Tau Medical by 185.7% in the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock worth $534,000 after purchasing an additional 70,081 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new position in shares of Alpha Tau Medical in the first quarter worth about $286,000. 2.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on DRTS shares. Barclays upped their price target on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, June 4th. Piper Sandler boosted their price objective on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 19th. Citigroup upped their target price on Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Alpha Tau Medical in a report on Tuesday, June 2nd. Finally, LADENBURG THALM/SH SH lifted their price target on Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $12.60.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.